Alpha Tau Medical Ltd. (DRTS)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.

Ticker
DRTS
Exchange
Nasdaq
Sector
Healthcare
Industry
Biotechnology
Market cap
$1.06B
52-week range
$3.43 - $15.79

Valuation

Share price
$12.01 (close of Nov 18, 2026)
P/E (TTM)
-22.66x
Price to book
13.71x
Price to free cash flow
-32.27x
Enterprise value
$993.82M
Book value per share
$0.88

Price performance

PeriodChange
1 day-0.66%
5 days-14.34%
1 month-2.28%
3 months-15.78%
6 months+19.74%
Year to date+142.63%
1 year+226.36%
3 years+293.77%
5 years+21.19%
All time+18.91%

Short interest

As of
Oct 30, 2026
Short % of float
6.12%
Shares short
3.92M
Days to cover
8.10
Change since prior report
+14.06%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-55.29%
Return on invested capital
-46.56%
Return on assets
-40.35%
Return on capital employed
-44.45%

Cash flow and balance sheet

Free cash flow yield (TTM)
-3.10%
Current ratio
7.45x
Net debt to EBITDA
1.54x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
EBITDA
-$41.06M
Net income
-$42.63M
Earnings per share
$-0.53
Research and development
$32.06M
Interest expense
$347.00K
Shares outstanding
80.58M

Income statement by year

Period endNet incomeEPS
2025-12-31-$42.63M-$0.53
2024-12-31-$31.75M-$0.45
2023-12-31-$29.16M-$0.42
2022-12-31-$33.76M-$0.53
2021-12-31-$27.27M-$0.67
2020-12-31-$8.88M-$0.22
2019-12-31-$8.37M-$0.25

Margins and returns by year

Period endReturn on equityReturn on capital
2025-12-31-55.29%-46.56%
2024-12-31-50.67%-47.93%
2023-12-31-34.52%-36.50%
2022-12-31-31.95%-28.99%

Cash and debt by year

Period endCash
2025-12-31$76.90M
2024-12-31$62.85M
2023-12-31$84.94M
2022-12-31$104.53M
2021-12-31$31.32M
2020-12-31$15.60M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$32.76M$10.62M
2024-12-31-$22.02M$9.92M
2023-12-31-$24.36M$7.93M
2022-12-31-$24.78M$6.75M
2021-12-31-$14.74M$812.00K
2020-12-31-$11.02M$596.00K
2019-12-31-$8.20M$546.00K

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026
Consensus EPS estimate
$-0.15

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-10Jun 2026-$0.14
2026-05-18Mar 2026-$0.13
2026-03-09Dec 2025-$0.13
2025-11-20Sep 2025-$0.12
2025-08-11Jun 2025-$0.12
2025-05-19Mar 2025-$0.14
2025-03-12Dec 2024-$0.13
2024-11-19Sep 2024-$0.13

Filings and sources

Company website
alphatau.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades